Targeting a mitochondrial protein to improve asthma treatment
Mitochondrial translocator protein: a target for bronchodilation
['FUNDING_R01'] · THOMAS JEFFERSON UNIVERSITY · NIH-10849840
This study is looking at a new way to help people with asthma by focusing on a special protein that could lead to better medications for relaxing the muscles in the airways, making it easier to breathe.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | THOMAS JEFFERSON UNIVERSITY (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10849840 on ClinicalTrials.gov |
What this research studies
This research investigates a new approach to managing asthma by targeting a specific mitochondrial protein known as the Translocator Protein (TSPO). The goal is to develop new drugs that can effectively relax airway smooth muscle and prevent bronchoconstriction, which is a common issue for asthma patients. The research involves various models, including human cells and animal studies, to understand how TSPO can be manipulated to improve airway function. By exploring the underlying mechanisms of how this protein affects muscle contraction, the researchers aim to create more effective bronchodilators.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with asthma who experience frequent bronchoconstriction and have not achieved optimal control with current treatments.
Not a fit: Patients with asthma who have well-controlled symptoms or those who do not respond to bronchodilators may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new asthma medications that provide better control of symptoms for patients.
How similar studies have performed: While targeting mitochondrial proteins for asthma treatment is a novel approach, similar strategies in other areas of respiratory medicine have shown promise.
Where this research is happening
PHILADELPHIA, UNITED STATES
- THOMAS JEFFERSON UNIVERSITY — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NAYAK, AJAY — THOMAS JEFFERSON UNIVERSITY
- Study coordinator: NAYAK, AJAY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.